Psychedelic-Assisted Therapy: A Guide to Substances, Research, Safety, and Legal Access

For decades, psychedelic substances were associated almost exclusively with counterculture and recreational use. That picture has changed dramatically. Today, leading research institutions, including Johns Hopkins, NYU, Imperial College London, and MAPS (the Multidisciplinary Association for Psychedelic Studies), are running rigorous clinical trials studying these substances as treatments for some of the most difficult-to-treat mental health conditions.

This is not about taking psychedelics casually. Psychedelic-assisted therapy is a structured clinical process that combines carefully dosed substances with professional therapeutic support. The results from clinical research have been striking enough to earn multiple FDA breakthrough therapy designations and to shift how the medical community thinks about conditions like PTSD, depression, and addiction.

This guide covers what the science actually shows, which substances are being studied, how therapy sessions work, who should and should not consider these treatments, and how to access legal options today.

What Is Psychedelic-Assisted Therapy?

Psychedelic-assisted therapy is the supervised administration of a psychedelic or psychedelic-related substance within a clinical or therapeutic context. It is not simply taking a drug. The therapy model involves three distinct phases:

1. Preparation sessions: Before any substance is administered, the patient works with trained therapists to establish trust, set intentions, discuss expectations, and review their mental health history. This phase typically involves two or more sessions.
2. Dosing session: The patient takes the substance in a controlled environment, usually a comfortable room designed to feel safe and calm. One or two trained therapists remain present throughout the session, which can last anywhere from a few hours (ketamine) to six or more hours (psilocybin). The therapists offer support but generally allow the patient to direct their own experience.
3. Integration sessions: In the days and weeks following the dosing session, the patient meets with therapists to process and make sense of their experience. This is where lasting therapeutic change is consolidated. Integration is widely considered the most important part of the process.

The combination of substance and therapy is what sets this apart from both recreational psychedelic use and conventional psychiatric medication. The substance creates a window of heightened neuroplasticity and emotional openness; the therapy provides the framework to turn that window into meaningful psychological change [3].

How Psychedelics Work in the Brain

Understanding why psychedelics can produce therapeutic effects requires a look at what they do in the brain. While the full picture is still being mapped out, several key mechanisms have been identified:

Default Mode Network Disruption

The default mode network (DMN) is a set of interconnected brain regions that are most active when we are engaged in self-referential thinking: ruminating, worrying, replaying the past, projecting into the future. In conditions like depression and PTSD, the DMN tends to be overactive, trapping people in rigid, repetitive thought patterns.

Classic psychedelics (psilocybin, LSD, DMT) temporarily reduce activity in the DMN. This disruption is associated with the experience of ego dissolution and the sense that rigid mental patterns have been loosened or “reset” [4].

Increased Neural Connectivity

Under the influence of psychedelics, brain regions that do not normally communicate begin to connect. Imaging studies show dramatically increased cross-talk between neural networks during psychedelic states. This increased connectivity may explain the novel insights, emotional breakthroughs, and perspective shifts that patients report [5].

Neuroplasticity

Psychedelics, particularly psilocybin and LSD, promote the growth of new neural connections (synaptogenesis) and the strengthening of existing ones. Animal studies have shown increased dendritic spine density after a single dose. This enhanced plasticity may create a biological window during which new patterns of thought and behavior can be established more easily [6].

Enhanced Emotional Processing

MDMA works through a different mechanism than classic psychedelics. It increases the release of serotonin, dopamine, and oxytocin while reducing activity in the amygdala, the brain’s fear center. This combination allows people to revisit traumatic memories with reduced fear and increased feelings of safety and compassion. For PTSD patients, this can be transformative [7].

Substances Being Studied and Used

Psilocybin

Psilocybin is the active compound in “magic mushrooms.” It is converted to psilocin in the body, which then acts on serotonin 2A receptors. Psilocybin sessions typically last 4 to 6 hours.

Research highlights:

• Treatment-resistant depression: A landmark 2022 trial published in the New England Journal of Medicine found that a single 25mg dose of psilocybin produced significant and sustained reductions in depression scores compared to lower doses [1].
• Alcohol use disorder: A 2022 study in JAMA Psychiatry showed that psilocybin-assisted therapy significantly reduced heavy drinking days compared to placebo [8].
• Smoking cessation: An open-label pilot study at Johns Hopkins found that 80% of participants remained abstinent from smoking at 6-month follow-up after psilocybin-assisted therapy [9].
• Cancer-related distress: Both NYU and Johns Hopkins studies demonstrated rapid, large, and sustained reductions in anxiety and depression in patients with life-threatening cancer diagnoses [10].

MDMA (3,4-Methylenedioxymethamphetamine)

MDMA is not a classic psychedelic. It is classified as an entactogen, meaning it produces feelings of emotional closeness, empathy, and well-being. Sessions typically last 6 to 8 hours.

The most advanced clinical program for MDMA is in PTSD treatment:

• Phase 3 trials conducted by MAPS showed that 71% of participants no longer met diagnostic criteria for PTSD after three MDMA-assisted therapy sessions, compared to 48% in the placebo group [2].
• The FDA declined to approve MDMA-assisted therapy in 2024, citing concerns about trial methodology and requesting additional data. The regulatory path continues, and additional trials are underway.
• MDMA works differently from SSRIs and other standard PTSD medications. Rather than dampening symptoms, it allows patients to engage directly with traumatic material in a state of reduced fear.

Ketamine

Ketamine is an anesthetic and dissociative drug that has been used in medicine since the 1960s. It is currently the only psychedelic-related substance that is broadly legal and available for clinical use in the United States.

• Mechanism: Ketamine blocks NMDA glutamate receptors, leading to rapid increases in brain-derived neurotrophic factor (BDNF) and synaptogenesis. Its antidepressant effects can begin within hours, unlike SSRIs, which take weeks [11].
• Esketamine (Spravato): An FDA-approved nasal spray form of ketamine specifically indicated for treatment-resistant depression. Administered in certified healthcare settings.
• IV and sublingual ketamine: Available off-label through hundreds of ketamine clinics across the U.S. Protocols vary widely between clinics in terms of dosing, therapy integration, and follow-up.
• Ketamine’s effects are typically shorter-lasting than those of classic psychedelics, and many patients require repeated sessions for sustained benefit.

LSD (Lysergic Acid Diethylamide)

LSD was actually the first psychedelic studied in a clinical context, with research dating back to the 1950s. Modern trials are revisiting LSD for anxiety, depression, and cluster headaches. Sessions last 8 to 12 hours, which makes the logistics more demanding. Recent clinical trials have shown promising results for generalized anxiety disorder [12].

Ayahuasca and DMT

Ayahuasca is a plant-based brew traditionally used in South American shamanic practices. It contains DMT (dimethyltryptamine) combined with MAO inhibitors that allow DMT to be orally active. Sessions can last 4 to 6 hours and often involve intense visionary experiences and purging (vomiting, which practitioners consider part of the healing process).

Research on ayahuasca for treatment-resistant depression has shown promising early results in small trials [13]. Synthetic DMT, which produces a very short but intense experience (15 to 30 minutes), is also being studied as a faster-acting alternative.

Ibogaine

Ibogaine is derived from the root bark of the African iboga plant. It has attracted significant attention for its potential to treat opioid addiction, with some reports of dramatically reduced withdrawal symptoms and cravings after a single session. However, ibogaine carries notable cardiac risks (QT prolongation) and has been associated with fatalities, making medical screening and monitoring critical [14].

5-MeO-DMT

5-MeO-DMT is a potent, short-acting psychedelic found naturally in the venom of the Sonoran Desert toad (Bufo alvarius) and also produced synthetically. The experience lasts 15 to 45 minutes and is described as intensely mystical. Preliminary research suggests potential for treatment-resistant depression and anxiety, but clinical data remains limited. Synthetic 5-MeO-DMT is preferred over toad-derived sources for both ethical and safety reasons.

Conditions Being Researched

The current clinical research pipeline covers a surprisingly wide range of conditions:

• PTSD: MDMA is the lead compound. Phase 3 data is strong. The therapy appears to work by allowing patients to process traumatic memories without being overwhelmed by fear responses.
• Treatment-resistant depression: Psilocybin and ketamine are the primary substances. Both have shown the ability to produce rapid antidepressant effects in patients who have not responded to multiple conventional medications.
• Addiction: Psilocybin is being studied for alcohol use disorder, tobacco dependence, and opioid use disorder. Ibogaine is being researched for opioid withdrawal.
• Anxiety in terminal illness: Psilocybin has consistently shown the ability to reduce existential distress, depression, and anxiety in patients facing a life-threatening diagnosis.
• OCD: Early-stage research on psilocybin for obsessive-compulsive disorder has shown preliminary promise, with some patients reporting significant symptom reduction.
• Eating disorders: Pilot studies are exploring psilocybin for anorexia nervosa, with the hypothesis that psychedelic experiences can disrupt the rigid, self-critical thought patterns central to the disorder.

Legal Status and Access

The legal landscape for psychedelic therapy is evolving rapidly, but it remains complex. Here is where things stand:

Currently Legal

• Ketamine: Legal throughout the U.S. for off-label use. Available via IV infusion clinics, intramuscular injection, and sublingual lozenges. Esketamine (Spravato) is FDA-approved specifically for treatment-resistant depression and major depressive disorder with suicidal ideation.
• Psilocybin in Oregon: Oregon’s Measure 109 created a regulated framework for psilocybin services. Licensed service centers allow adults 21 and older to receive psilocybin in supervised settings, regardless of diagnosis. This is not a prescription model; it is a service model with trained “facilitators” rather than therapists.
• Psilocybin in Colorado: Colorado’s Natural Medicine Health Act is establishing a similar regulated access program for psilocybin and other natural psychedelics. Licensed healing centers are beginning to open.

Regulatory Pathways

• FDA breakthrough therapy designations: Both psilocybin (for treatment-resistant depression) and MDMA (for PTSD) have received breakthrough therapy designation from the FDA, which is meant to speed the review process for drugs that show substantial improvement over existing treatments.
• MDMA regulatory status: Despite strong Phase 3 data, the FDA did not approve MDMA-assisted therapy on initial review, requesting additional data on long-term safety and trial methodology. MAPS and its public benefit corporation, Lykos Therapeutics, are working on next steps.
• State-level changes: Multiple states are considering legislation to decriminalize or create regulated access programs for psychedelics. The policy landscape continues to shift.

Clinical Trials

Participating in a clinical trial is another way to access psychedelic-assisted therapy legally. Trials are ongoing at major academic medical centers for various conditions. ClinicalTrials.gov is the primary database for finding active studies.

What a Therapy Session Actually Looks Like

One of the most common questions is: what actually happens during a psychedelic therapy session? While protocols vary by substance and clinical setting, the general structure is consistent:

Preparation (1 to 3 Sessions Before Dosing)

• Detailed psychiatric and medical screening
• Establishing rapport with the therapist(s) who will be present during the dosing session
• Discussion of the patient’s treatment history, goals, and concerns
• Education about what to expect during the experience, including challenging moments
• Developing a framework for working with difficult emotions or memories that may arise

The Dosing Session

• Conducted in a comfortable room, often with a couch or recliner, eyeshades, and curated music playlists
• One or two therapists remain present for the entire session
• The substance is administered (orally for psilocybin and MDMA, IV or sublingual for ketamine)
• The patient is encouraged to turn inward, often wearing eyeshades and listening to music
• Therapists offer gentle support and reassurance but generally do not direct the experience
• Session duration varies: 1 to 2 hours for ketamine, 4 to 6 hours for psilocybin, 6 to 8 hours for MDMA
• Vital signs are monitored throughout
• The patient remains at the clinic until effects have subsided and should not drive afterward

Integration (2 or More Sessions After Dosing)

• Occurs in the days and weeks following the dosing session
• The patient discusses what they experienced, felt, and learned
• Therapists help connect insights from the experience to the patient’s real-life struggles and goals
• Behavioral changes, new perspectives, and emotional processing are supported and reinforced
• Some protocols include group integration sessions

Integration is not optional. It is the process that translates an acute psychedelic experience into lasting therapeutic benefit. Without proper integration, even a powerful experience can fade without producing meaningful change.

Safety, Risks, and Contraindications

Psychedelic-assisted therapy is not risk-free, and it is not appropriate for everyone. Honest discussion of safety is essential.

Who Should Not Receive Psychedelic Therapy

• Personal or family history of psychotic disorders: Schizophrenia, schizoaffective disorder, and bipolar I disorder with psychotic features are generally considered absolute contraindications for classic psychedelics. Psychedelics can trigger or worsen psychotic episodes in vulnerable individuals [15].
• Certain medications: SSRIs and SNRIs can blunt the effects of serotonergic psychedelics (psilocybin, LSD) and may increase the risk of serotonin syndrome. Lithium combined with psychedelics has been associated with seizures. MAOIs and ayahuasca require careful dietary and medication restrictions. Medication interactions must be thoroughly reviewed.
• Cardiac conditions: MDMA increases heart rate and blood pressure and is contraindicated in people with uncontrolled hypertension, heart failure, or a history of cardiac events.
• Pregnancy: Psychedelic therapy is not recommended during pregnancy due to unknown effects on fetal development.

Potential Risks

• Challenging experiences (“bad trips”): Psychedelic sessions can involve difficult emotions, frightening visions, or intense anxiety. In a therapeutic setting, trained professionals help patients work through these experiences, but they can still be distressing.
• Hallucinogen Persisting Perception Disorder (HPPD): A rare condition in which visual disturbances persist after psychedelic use. The incidence in clinical settings is very low.
• Cardiovascular effects: Particularly relevant for MDMA and, to a lesser extent, classic psychedelics.
• Psychological vulnerability: In the days following a session, patients may feel emotionally raw or destabilized. Adequate therapeutic support during this window is important.
• Abuse potential: While classic psychedelics (psilocybin, LSD, DMT) have low addiction potential, ketamine and MDMA do carry some risk of misuse, particularly outside of clinical settings.

Set and Setting

The concept of “set and setting” is foundational to psychedelic therapy. “Set” refers to the patient’s mindset going into the experience: their expectations, emotional state, and intentions. “Setting” refers to the physical and social environment. Research consistently shows that positive outcomes are strongly associated with proper preparation, a safe physical environment, and the presence of trained, trustworthy therapists. This is why pursuing psychedelic experiences outside of clinical or supervised settings carries substantially higher risks.

Finding Legal Options

If you are interested in pursuing psychedelic-assisted therapy, here are the currently available legal pathways:

Ketamine Clinics

Ketamine clinics operate in most major U.S. cities. Quality varies significantly. When evaluating a clinic, look for:

• Medical providers who conduct thorough screening and assessments
• Integration therapy offered as part of the treatment package
• Clear protocols for monitoring during sessions
• Transparent pricing and realistic expectations about outcomes
• Avoid clinics that operate on a high-volume, minimal-interaction model

Oregon Psilocybin Service Centers

Oregon’s licensed psilocybin service centers offer supervised psilocybin sessions to adults 21 and older. No diagnosis is required. Sessions include preparation, dosing, and integration support. Facilitators are trained through state-approved programs. The Oregon Psilocybin Services section of the Oregon Health Authority website maintains a list of licensed centers.

Colorado Natural Medicine

Colorado is rolling out its regulated access program. Licensed healing centers are becoming operational, offering psilocybin and potentially other natural medicines in supervised settings.

Clinical Trials

For substances not yet approved (MDMA, psilocybin in most states, LSD), clinical trials offer a legal path to access. Search ClinicalTrials.gov for active studies. Many major medical centers are actively recruiting participants.

Cost Considerations

Psychedelic-assisted therapy is generally not covered by insurance, with the exception of esketamine (Spravato), which some insurance plans cover.

• Ketamine infusion: Individual IV sessions typically cost $400 to $800. A standard initial course involves 6 sessions over 2 to 3 weeks, totaling $2,400 to $4,800. Sublingual and at-home ketamine programs can be less expensive but involve trade-offs in supervision.
• Oregon psilocybin sessions: A full session (preparation, dosing, and integration) generally costs $1,500 to $3,500, depending on the service center and session length.
• Clinical trials: Participation in clinical trials is typically free. Some trials also cover travel expenses.

Cost is a genuine barrier to access. Advocacy organizations are working on insurance coverage pathways, sliding-scale options, and equity programs to broaden access.

The Integration Process: Where the Real Work Happens

If there is one thing that clinicians and researchers in this field agree on, it is that the psychedelic experience itself is not the therapy. Integration is the therapy.

Integration refers to the ongoing process of making sense of what occurred during a psychedelic session and translating those insights into real changes in daily life. This can involve:

• Formal therapy sessions: Working with a therapist trained in psychedelic integration to process the experience, address new material that surfaced, and build on shifts in perspective.
• Journaling: Writing about the experience, emotions, and insights that arose. This can help consolidate memory and meaning from the session.
• Body-based practices: Yoga, breathwork, somatic experiencing, and other body-oriented practices can support the integration of material that emerged during the session.
• Community support: Integration circles and peer support groups are available in many cities and online. Sharing experiences in a supportive group context can normalize and deepen the integration process.
• Lifestyle changes: Many patients report that psychedelic experiences motivate changes in relationships, habits, diet, exercise, or career. Integration supports acting on these motivations rather than letting them fade.

The integration window, the period of enhanced neuroplasticity following a psychedelic experience, is thought to last days to weeks. Taking advantage of this window through active integration work is how temporary states become lasting traits.

Risks vs. Benefits: An Honest Assessment

The clinical data for psychedelic-assisted therapy is genuinely promising. Effect sizes in many trials are larger than those seen with conventional medications for the same conditions. For people who have not responded to standard treatments, these therapies represent a meaningful new option.

At the same time, it is important to be honest about the limitations:

• Long-term data is still limited. Most trials have follow-up periods of 6 to 12 months.
• Not everyone responds. Success rates, while high compared to existing treatments, are not 100%.
• The therapy component is at least as important as the substance. Access to skilled therapists trained in this modality matters enormously.
• The field is young and regulatory frameworks are still being built. Quality control varies.
• Hype can outpace evidence. Not every claim made about psychedelics in popular media is supported by rigorous science.

The strongest case for psychedelic-assisted therapy is for people with conditions that have not responded to conventional approaches, who can access supervised clinical settings, and who are willing to engage fully in the preparation and integration process.

Related Reading

• Understanding PTSD: Symptoms, Treatment, and Recovery
• Treatment-Resistant Depression: When Standard Medications Are Not Enough
• Ketamine Therapy: What to Expect, Costs, and Finding a Provider
• Addiction and Recovery: Evidence-Based Approaches
• Integrative Approaches to Mental Health

Frequently Asked Questions

Does psychedelic-assisted therapy actually work, and for what?

Trials show promising results for treatment-resistant depression, PTSD, anxiety, and addiction, often with larger effect sizes than conventional medications. A Phase 3 MDMA study found 71% of participants no longer met PTSD criteria. Evidence is still early, follow-up is limited to 6 to 12 months, and not everyone responds.

Is psychedelic therapy legal, and where can I access it?

It depends on the substance. Ketamine is legal off-label across the U.S., and esketamine (Spravato) is FDA-approved for treatment-resistant depression. Psilocybin is only accessible through licensed programs in Oregon and Colorado for adults 21 and over. MDMA is not FDA-approved. Clinical trials are another route.

How much does psychedelic-assisted therapy cost?

Costs are significant and usually not covered by insurance. Ketamine IV sessions typically run $400 to $800 each, with a standard 6-session course totaling $2,400 to $4,800. Oregon psilocybin sessions generally cost $1,500 to $3,500. Esketamine is the exception for insurance, and clinical trial participation is usually free.

What are the risks and who should not do it?

A personal or family history of psychotic disorders is an absolute contraindication. It is not advised for people on SSRIs, SNRIs, or lithium, those with uncontrolled hypertension or cardiac conditions, or during pregnancy. Risks include challenging experiences, cardiovascular effects, psychological vulnerability afterward, and rare conditions like HPPD.

What does a typical session involve?

The process has three stages. Preparation covers psychiatric and medical screening and building rapport over 1 to 3 sessions. During dosing, you rest in a comfortable room with eyeshades and music while one or two therapists stay present and monitor vitals. Integration afterward, considered the most important part, helps connect insights to daily life.

Who is a good candidate for this treatment?

The strongest case is for people whose conditions have not responded to conventional approaches, who can access supervised clinical settings, and who are willing to engage fully in preparation and integration. Because a psychotic disorder history and certain medications rule people out, careful medical and psychiatric screening is an essential first step.

References

1. Goodwin GM, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443
2. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. doi:10.1038/s41591-021-01336-3
3. Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017;42(11):2105-2113. doi:10.1177/0269881120916143
4. Carhart-Harris RL, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109(6):2138-2143. doi:10.1073/pnas.1119598109
5. Petri G, et al. Homological scaffolds of brain functional networks. J R Soc Interface. 2014;11(101):20140873. doi:10.1098/rsif.2014.0873
6. Ly C, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022
7. Carhart-Harris RL, et al. The effect of MDMA on amygdala response to emotional faces. Biol Psychiatry. 2015;78(8):e33-e35. doi:10.1016/j.biopsych.2015.10.025
8. Bogenschutz MP, et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. JAMA Psychiatry. 2022;79(10):953-962. doi:10.1001/jamapsychiatry.2022.2096
9. Johnson MW, et al. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014;28(11):983-992. doi:10.1177/0269881114548296
10. Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. J Psychopharmacol. 2016;30(12):1181-1197. doi:10.1177/0269881116675513
11. Li N, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-964. doi:10.1126/science.1190287
12. Holze F, et al. LSD for the treatment of anxiety in patients with and without a life-threatening disease. Biol Psychiatry. 2023;93(7):613-621. doi:10.1016/j.biopsych.2022.08.025
13. Palhano-Fontes F, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med. 2019;49(4):655-663. doi:10.1177/0269881116675512
14. Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24-36. doi:10.1177/0269881118791597
15. Johnson MW, et al. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83-102. doi:10.1177/0269881114565653
16. Reiff CM, et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177(5):391-410. doi:10.1176/appi.ajp.2019.19010035

About the medical reviewer

Dr. Bronwyn Holmes, MD, FAARFM is a physician specialising in regenerative medicine, advanced peptide therapeutics, exosome and stem cell biology, hormonal health, and longevity. Last reviewed July 5, 2026.